613 related articles for article (PubMed ID: 34504767)
21. [Chronic lymphocytic leukemia: update on pathophysiology and management].
Suzumiya J
Rinsho Ketsueki; 2018; 59(5):511-520. PubMed ID: 29877241
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia.
Chavez JC; Sahakian E; Pinilla-Ibarz J
Core Evid; 2013; 8():37-45. PubMed ID: 23717217
[TBL] [Abstract][Full Text] [Related]
23. [Haemorrhagic complications following ibrutinib intake after dermatological surgery].
Lebas D; Preta LH; Leguern A; Modiano P; Wiart T
Ann Dermatol Venereol; 2020 Nov; 147(11):775-779. PubMed ID: 32917401
[TBL] [Abstract][Full Text] [Related]
24. β2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia.
Thompson PA; O'Brien SM; Xiao L; Wang X; Burger JA; Jain N; Ferrajoli A; Estrov Z; Keating MJ; Wierda WG
Cancer; 2016 Feb; 122(4):565-73. PubMed ID: 26588193
[TBL] [Abstract][Full Text] [Related]
25. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
Brown JR; Barrientos JC; Barr PM; Flinn IW; Burger JA; Tran A; Clow F; James DF; Graef T; Friedberg JW; Rai K; O'Brien S
Blood; 2015 May; 125(19):2915-22. PubMed ID: 25755291
[TBL] [Abstract][Full Text] [Related]
26. Current Treatment of Chronic Lymphocytic Leukemia.
Jamroziak K; Puła B; Walewski J
Curr Treat Options Oncol; 2017 Jan; 18(1):5. PubMed ID: 28185174
[TBL] [Abstract][Full Text] [Related]
27. Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Brochard J; Morio F; Mahe J; Le Pape P; Guimard T; Mahe B; Leterrier M; Morrier M; Raffi F; Boutoille D
Med Mal Infect; 2020 Nov; 50(8):742-745. PubMed ID: 32777360
[TBL] [Abstract][Full Text] [Related]
28. Cutaneous Mucormycosis Following a Bullous Pemphigoid Flare in a Chronic Lymphocytic Leukemia Patient on Ibrutinib.
Stein MK; Karri S; Reynolds J; Owsley J; Wise A; Martin MG; Zare F
World J Oncol; 2018 Apr; 9(2):62-65. PubMed ID: 29760835
[TBL] [Abstract][Full Text] [Related]
29. Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Gayko U; Fung M; Clow F; Sun S; Faust E; Price S; James D; Doyle M; Bari S; Zhuang SH
Ann N Y Acad Sci; 2015 Nov; 1358():82-94. PubMed ID: 26348626
[TBL] [Abstract][Full Text] [Related]
30. Ibrutinib-associated invasive fungal diseases in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: An observational study.
Ruchlemer R; Ben-Ami R; Bar-Meir M; Brown JR; Malphettes M; Mous R; Tonino SH; Soussain C; Barzic N; Messina JA; Jain P; Cohen R; Hill B; Mulligan SP; Nijland M; Herishanu Y; Benjamini O; Tadmor T; Okamoto K; Arthurs B; Gottesman B; Kater AP; Talha M; Eichhorst B; Korem M; Bogot N; De Boer F; Rowe JM; Lachish T
Mycoses; 2019 Dec; 62(12):1140-1147. PubMed ID: 31520441
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
[TBL] [Abstract][Full Text] [Related]
32. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
33. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
Wiestner A
Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
[TBL] [Abstract][Full Text] [Related]
34. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.
Dias AL; Jain D
Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470
[TBL] [Abstract][Full Text] [Related]
35. Ibrutinib-induced polyneuropathy: A case report.
Cömert P; Albayrak M; Yıldız A; Şahin O; Öztürk HB; Reis Aras M
J Oncol Pharm Pract; 2020 Sep; 26(6):1501-1504. PubMed ID: 32028841
[TBL] [Abstract][Full Text] [Related]
36. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
[TBL] [Abstract][Full Text] [Related]
37. Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia.
Lee A; Sandhu S; Imlay-Gillespie L; Mulligan S; Shumack S
Australas J Dermatol; 2017 Nov; 58(4):e240-e242. PubMed ID: 28295171
[TBL] [Abstract][Full Text] [Related]
38. Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Barrientos JC; O'Brien S; Brown JR; Kay NE; Reddy NM; Coutre S; Tam C; Mulligan S; Jaeger U; Devereux S; Pocock C; Robak T; Schuster SJ; Schuh A; Gill D; Bloor A; Dearden C; Moreno C; Cull G; Hamblin M; Jones JA; Eckert K; Solman IG; Suzuki S; Hsu E; James DF; Byrd JC; Hillmen P
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):803-813.e7. PubMed ID: 30249389
[TBL] [Abstract][Full Text] [Related]
39. Cranial aspergillosis in a patient receiving ibrutinib for chronic lymphocytic leukemia.
Beresford R; Dolot V; Foo H
Med Mycol Case Rep; 2019 Jun; 24():27-29. PubMed ID: 30899641
[TBL] [Abstract][Full Text] [Related]
40. [Improvement of autoimmune cytopenia with ibrutinib in a chronic lymphocytic leukemia patient complicated by monoclonal immunoglobulin deposition disease].
Nakamura M; Yoshioka S; Yamashita D; Hara S; Ishikawa T
Rinsho Ketsueki; 2019; 60(10):1449-1454. PubMed ID: 31695006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
